SRL
TSHA icon

Scientech Research LLC’s Taysha Gene Therapies TSHA Stock Holding History

Scientech Research LLC’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$94K Buy
21,040
+2,864
+16% +$13.3K 0.08% 345
2025
Q4 		$100K Buy
+18,176
New +$88.3K 0.06% 409
2024
Q3 		– Sell
-43,350
Closed -$97.1K – 847
2024
Q2 		$97.1K Buy
+43,350
New +$126K 0.02% 546

Other funds holding TSHA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Scientech Research LLC's TSHA Position: Q1 2026 in Review

Scientech Research LLC increased its Taysha Gene Therapies (TSHA) stake by 16% in Q1 2026, buying an estimated $13.3K and bringing the position to 21,040 shares worth $94K. The position accounts for 0.08% of the portfolio, ranked #345.

Scientech Research LLC first reported a position in TSHA in Q2 2024 and has held it in 3 quarters since. The position peaked at $100K in Q4 2025. 191 funds tracked by Wall St. Rank hold TSHA as of Q1 2026.

  • Scientech Research LLC held 21,040 shares of Taysha Gene Therapies worth $94K as of Q1 2026.
  • Scientech Research LLC bought 2,864 Taysha Gene Therapies shares in Q1 2026, an estimated $13.3K.
  • Taysha Gene Therapies made up 0.08% of Scientech Research LLC's portfolio in Q1 2026, its #345 holding.
  • Scientech Research LLC first reported a position in Taysha Gene Therapies in Q2 2024 and has held it in 3 quarters since.
  • Scientech Research LLC's Taysha Gene Therapies position peaked at $100K in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2026.

Based on Scientech Research LLC's 13F filing for Q1 2026, filed 15 May 2026.